ストックスクリーナーアプリを入手
0.00
100.00%
-8.16
前日終値:
$8.16
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$564.26M
収益：
-
当期純損益:
$-30.04M
株価収益率:
0.00
EPS:
-1.58
ネットキャッシュフロー:
$-27.38M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$8.345
Regulus Therapeutics Inc Stock (RGLS) Company Profile
名前
Regulus Therapeutics Inc
セクター
電話
858-202-6300
住所
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
0.00 | 564.26M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | 開始されました | Oppenheimer | Outperform |
| 2024-03-18 | 開始されました | Leerink Partners | Outperform |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | 開始されました | Leerink Partners | Outperform |
| 2017-06-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-03-06 | 繰り返されました | Wedbush | Outperform |
| 2017-01-30 | ダウングレード | Needham | Buy → Hold |
| 2017-01-30 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-11-02 | 繰り返されました | Needham | Buy |
| 2016-07-25 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | FBR Capital | Outperform |
| 2016-06-28 | 繰り返されました | Needham | Buy |
| 2016-06-07 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-04-13 | 開始されました | Chardan Capital Markets | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-06-09 | 開始されました | Guggenheim | Buy |
| 2015-04-21 | 再開されました | FBR Capital | Outperform |
| 2014-11-24 | 開始されました | Deutsche Bank | Buy |
| 2014-08-07 | 繰り返されました | FBR Capital | Outperform |
| 2013-08-14 | 繰り返されました | Needham | Buy |
すべてを表示
Regulus Therapeutics Inc (RGLS) 最新ニュース
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.
Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma
Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times
Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com
Novartis Launches Tender Offer for Regulus Therapeutics Takeover - MarketScreener
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - MSN
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
Regulus Therapeutics Inc (RGLS) 財務データ
収益
当期純利益
現金流量
EPS
2.10%
1.57%
大文字化:
|
ボリューム (24 時間):